Please use this identifier to cite or link to this item:
Title: Characterization of signaling pathways and significance of the axon guidance molecule plexin-B3 in glioma progression
Authors: LI XINHUA
Keywords: plexin-B3, Sema5A, fascin-1, RhoGDIalpha, glioma, actin
Issue Date: 30-Jan-2009
Citation: LI XINHUA (2009-01-30). Characterization of signaling pathways and significance of the axon guidance molecule plexin-B3 in glioma progression. ScholarBank@NUS Repository.
Abstract: Plexins were originally characterized as cell surface receptors for the guidance molecule semaphorins in the nervous system. They have also been found to subserve important functions in various extraneuronal tissues including regulation of cancer progression. Plexin-B3, a new member of plexin-B subfamily, is a functional receptor for semaphorin 5A. In this study, we investigated the signaling pathways and the biological functions of plexin-B3 in glioma cell progression. Sema5A significantly inhibits human glioma cell migration and invasion through endogenous plexin-B3. Mechanistically, the induction of cell collapse, disruption of focal adhesions, disassembly of actin stress fibers, and inactivation of Rac1 are involved. Importantly, plexin-B3 recruits fascin-1 and regulates its phosphorylation, hence actin fibre dynamics. Further, Sema5A and plexin-B3 induce expression of the astrocytic marker GFAP as well as morphological changes that resemble differentiated astrocytes in human glioma. In C6 glioma cells, Sema5A and plexin-B3 suppress cell invasive growth by downregulation of Rac1 activation through RhoGDIN1. All these results demonstrate that Sema5A and plexin-B3 play an important role in anti-glioma progression through different mechanisms.
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
LiXH PDF.pdf11.6 MBAdobe PDF



Page view(s)

checked on Apr 19, 2019


checked on Apr 19, 2019

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.